General Information of Drug (ID: DMVBGIT)

Drug Name
BMS-180448 Drug Info
Synonyms
C20H18ClN5O2; BMS 180448; CHEMBL11802; 144264-47-1; BMS-180448; trans-N-(4-Chlorophenyl)-N'-cyano-N''-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)guanidine; Guanidine, N-(4-chlorophenyl)-N'-cyano-N''-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-, trans-; Bms 180426; AC1L3TUP; DTXSID90162661; BDBM50409908; BMS-180426; LS-173206; 1-(4-chlorophenyl)-3-cyano-2-[(3R,4S)-6-cyano-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]guanidine
Indication
Disease Entry ICD 11 Status REF
Angina pectoris BA40 Discontinued in Phase 2 [1]
Cross-matching ID
PubChem CID
60880
CAS Number
CAS 144301-94-0
TTD Drug ID
DMVBGIT

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nateglinide DMLK2QH Diabetic complication 5A2Y Approved [3]
Amiodarone DMUTEX3 Tachyarrhythmias BC71 Approved [3]
Dronedarone DMA8FS5 Angina pectoris BA40 Approved [4]
Dofetilide DMPN1TW Sinus rhythm disorder BC9Y Approved [3]
Amifampridine DMK08L3 LambertEaton myasthenic syndrome 8C62 Approved [5]
Minoxidil DMA2Z4F Alopecia ED70 Approved [3]
Pinacidil DMRADYL High blood pressure BA00 Approved [3]
Dalfampridine DMM0PDO Multiple sclerosis 8A40 Approved [6]
Ibutilide DMKXY2R Atrial fibrillation BC81.3 Approved [3]
Diazoxide DML1538 Congenital hyperinsulinism 5A4Y Approved [3]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Potassium channel unspecific (KC) TT1VOHK NOUNIPROTAC Agonist [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004365)
2 The novel cardioprotective agent BMS-180448 activates a potassium conductance in cardiac and vascular smooth muscle. Naunyn Schmiedebergs Arch Pharmacol. 1996 Oct;354(4):444-51.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
5 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
6 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.